The use of tirofiban with either low molecular weight heparin or unfractionated heparin: a novel anticoagulation regime for patients undergoing PCI.

TL;DRAbstract

Background: An invasive strategy has become the preferred mode of treatment for patients with high-risk acute coronary syndrome.1-3 Adjunctive pharmacotherapeutic agents inhibiting platelet dependent thrombosis have improved the safety and efficacy of percutaneous coronary intervention (PCI) in these patients.4 The glycoprotein (GP) IIb/IIIa receptor is considered the ‘final common pathway’ for platelet activation and this receptor is blocked by glycoprotein inhibitors such as tirofiban and abciximab. These drugs have been shown to reduce the morbidity and mortality of patients undergoing high-risk PCI.4, 5 The use of tirofiban at a dose at 10 mcg/kg bolus followed by an infusion of 0.15 mcg/kg/min during PCI has been evaluated in two large multicentre trials with controversial results suggesting inferior outcomes compared to abciximab, the first agent of its type produced for commercial use.6, 7 It has been hypothesised that an inferior clinical result has been the result of subtherap

Chat with Paper

AI Agents for this Paper